3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
5
Polycystic Ovary Syndrome
4
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Insulin Resistance
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma, Myeloid
1
Racism
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Infertility
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectum
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Brain Neoplasms
1
Anovulation
1
Interventions
pembrolizumab
9
Paclitaxel
9
Doxorubicin
6
Cyclophosphamide
6
Carboplatin
5
130-nm albumin-bound paclitaxel
5
durvalumab
3
yeast-CEA vaccine
2
talazoparib
2
sacituzumab govitecan
2
olaparib
2
glembatumumab vedotin
2
avelumab
2
Taxes
2
Radiotherapy
2
Leucovorin
2
Fluorouracil
2
Cisplatin
2
Capecitabine
2
Biopsy
2
Albumin-Bound Paclitaxel
2
ALT-803
2
zimberelimab
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab duocarmazine
1
tislelizumab
1
taxane
1
sabizabulin
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Triple Negative Breast Neoplasms
×
Metformin
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn